PHAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Phathom Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.66 Mil. Phathom Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.68 Mil. Phathom Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.97.
Phathom Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (0.00) to Sep. 2023 (0.97)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year. Phathom Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.00.
The historical data trend for Phathom Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phathom Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Phathom Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (0 | + | 1.208) | / | 1 ) | / | 0.682 |
= | 1.208 | / | 0.682 | ||||
= | 1.77 |
Phathom Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (Q: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Revenue (Q: Dec. 2023 ) |
= | ( (0.111 | + | 1.208) | / | 2 ) | / | 0.682 |
= | 0.6595 | / | 0.682 | ||||
= | 0.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals (NAS:PHAT) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Phathom Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 0.6595 | / | 0 | * | 365 / 4 | |
= |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Phathom Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2023 ) | / | Average Total Inventories (Q: Dec. 2023 ) |
= | 0 | / | 0.6595 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Molly Henderson | officer: CFO and CBO | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Asit Parikh | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Azmi Nabulsi | officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
David A Socks | director, officer: President, CEO, Treas. & Sec. | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Anthony J. Guzzo | officer: VP, Chief Accounting Officer | C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Mark Stenhouse | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael F Cola | director | 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945 |
Frazier Life Sciences Ix, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Jonathan S. Edwards | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 06-02-2023
By PRNewswire PRNewswire • 05-31-2023
By Marketwired • 09-05-2023
By PRNewswire • 08-25-2023
By sperokesalga sperokesalga • 06-12-2023
By PRNewswire PRNewswire • 06-01-2023
By Marketwired • 08-21-2023
By PRNewswire PRNewswire • 06-09-2023
By PRNewswire PRNewswire • 05-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.